DiaMedica Therapeutics
DMAC
98 hedge funds and large institutions have $79.2M invested in DiaMedica Therapeutics in 2026 Q1 according to their latest regulatory filings, with 20 funds opening new positions, 28 increasing their positions, 24 reducing their positions, and 12 closing their positions.
67% more first-time investments, than exits
New positions opened: 20 | Existing positions closed: 12
37% more call options, than puts
Call options by funds: $194K | Put options by funds: $142K
17% more repeat investments, than reductions
Existing positions increased: 28 | Existing positions reduced: 24
7% more funds holding
Funds holding: 92 → 98 (+6)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
0.68% less ownership
Funds ownership: 23.15% → 22.46% (-0.68%)
18% less capital invested
Capital invested by funds: $96M → $79.2M (-$16.8M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
+$1.32M |
| 2 |
Osaic Holdings
Scottsdale,
Arizona
|
+$576K |
| 3 |
ECM
ExodusPoint Capital Management
New York
|
+$476K |
| 4 |
CI
Corient IA
Miami,
Florida
|
+$475K |
| 5 |
SEI Investments
Oaks,
Pennsylvania
|
+$441K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
-$3.5M |
| 2 |
Wellington Management Group
Boston,
Massachusetts
|
-$825K |
| 3 |
FAM
Fred Alger Management
New York
|
-$662K |
| 4 |
Goldman Sachs
New York
|
-$555K |
| 5 |
Barclays
London,
United Kingdom
|
-$368K |
DMAC Hedge Fund Activity: Q1 2026 in Review
98 of the 8,127 institutional investors tracked by Wall St. Rank reported a position in DiaMedica Therapeutics (DMAC) for Q1 2026, worth a combined $79.2M — down 18% from $96M a quarter earlier.
Buyers outnumbered sellers: 20 funds opened new DMAC positions and 12 closed out — a net gain of 8 holders — while 28 added to existing stakes and 24 trimmed.
The largest buyer was Millennium Management, adding an estimated $1.32M. The largest seller was Morgan Stanley, cutting an estimated $3.5M.
- 98 institutional investors held DiaMedica Therapeutics (DMAC) as of Q1 2026, up from 92 in Q4 2025.
- Funds reported $79.2M of DiaMedica Therapeutics stock for Q1 2026, down 18% quarter-over-quarter.
- 20 funds opened new DiaMedica Therapeutics positions in Q1 2026 and 12 closed out, a net change of +8 holders.
- The largest DiaMedica Therapeutics buyer in Q1 2026 was Millennium Management, an estimated $1.32M added.
- The largest DiaMedica Therapeutics seller in Q1 2026 was Morgan Stanley, an estimated $3.5M sold.
Based on aggregated 13F filings for Q1 2026.